Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-α, VEGF-A, VEGF-C and midkine in gastroesophageal cancer patients

Clinical Biochemistry

Volumn 40, Issue 18, 2007, Pages 1353-1360

  Krzystek Korpacka, Malgorzata ^a   Matusiewicz, Malgorzata ^a   Diakowska, Dorota ^a   Grabowski, Krzysztof ^a   Blachut, Katarzyna ^a   Kustrzeba Wojcicka, Irena ^a   Banas, Teresa ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Cachexia; Gastroesophageal cancer; IL 1; IL 6; IL 8; Midkine; TNF ; VEGF A; VEGF C; Weight loss

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MIDKINE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VASCULOTROPIN C;

ADULT; ARTICLE; BLOOD CELL COUNT; BODY MASS; CACHEXIA; CANCER PATIENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CACHEXIA; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOKINES; ESOPHAGOGASTRIC JUNCTION; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; WEIGHT LOSS;

EID: 36348976492     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.07.013     Document Type: Article

References (58)

1. Tisdale M.J. Molecular pathways leading to cancer cachexia. Physiology 20 (2005) 340-348
2. Inui A. Cancer cachexia-anorexia syndrome: current issues in research and management. CA Cancer J. Clin. 52 (2002) 72-91
3. Takahashi Y., Yasumoto K., and Mai M. Chemotherapy under cachectic conditions and the possibility of cachexia-controlled chemotherapy. Oncol. Rep. 14 (2005) 135-140
4. Palesty J.A., and Dudrick S.J. What we have learned about cachexia in gastrointestinal cancer. Dig. Dis. 21 (2003) 198-213
5. Boddaert M.S., Gerritsen W.R., and Pinedo H.M. On our own way to targeted therapy for cachexia in cancer. Curr. Opin. Oncol. 18 (2006) 335-340
6. Deans C., and Wigmore S.J. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 8 (2005) 265-269
7. McCarthy D.O. Rethinking nutritional support for persons with cancer cachexia. Biol. Res. Nurs. 5 (2003) 3-17
8. Fearon K.C., Voss A.C., and Hustead D.S. Cancer Cachexia Study Group. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am. J. Clin. Nutr. 83 (2006) 1345-1350
9. Argiles J.M., Busquets S., Garcia-Martonez C., and Lopez-Soriano F. Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition 21 (2005) 977-985
10. Kadomatsu K., and Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 204 (2004) 127-143
11. Dvorak H.F. Angiogenesis: update 2005. J. Thromb. Haemost. 3 (2005) 1835-1842
12. Henson P.M., and Vandivier R.W. The matrix degrades, neutrophils invade. Nat. Med. 12 (2006) 280-281
13. Uehara K., Matsubara S., Kadomatsu K., Tsutsui J., and Muramatsu T. Genomic structure of human midkine (MK), a retinoic acid-responsive growth/differentiation factor. J. Biochem. 111 (1992) 563-567
14. Chilov D., Kukk E., Taira S., et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J. Biol. Chem. 272 (1997) 25176-25183
15. Tisdale M.J. Cachexia in cancer patients. Nat. Rev., Cancer 2 (2002) 862-871
16. Josko J., and Mazurek M. Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med. Sci. Monit. 10 (2004) RA89-RA98
17. Yeo M., Park H.K., Lee K.M., et al. Blockage of HSP 90 modulates Helicobacter pylori-induced IL-8 productions through the inactivation of transcriptional factors of AP-1 and NF-kappaB. Biochem. Biophys. Res. Commun. 320 (2004) 816-824
18. Uomo G., Gallucci F., and Rabitti P.G. Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management. JOP 7 (2006) 157-162
19. Enzinger P.C., and Mayer R.J. Esophageal cancer. N. Engl. J. Med. 349 (2003) 2241-2252
20. Mal F., Levard H., Denet Ch., Validire P., and Gayet B. Pre-operative predictive factors of early recurrence after resection of adenocarcinoma of the esophagus and cardia. Gastroenterol. Clin. Biol. 29 (2005) 1275-1278
21. Sobin L.H., and Wittekind Ch. TNM classification of malignant tumors. 6th ed. (2002), Jon Wiley and Sons, Hoeboken, NJ
22. Green F.L., Page D.L., Fleming I.D., et al. AJCC cancer staging manual. 6th ed. (2002), Springer Verlag, New York
23. Martignoni M.E., Kunze P., Hildebrandt W., et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin. Cancer Res. 11 (2005) 5802-5808
24. Krzystek-Korpacka M., Matusiewicz M., Grabowski K., et al. Immunoenzymatic method for midkine determination in serum. Adv. Clin. Exp. Med. 15 (2006) 247-252
25. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin. Chem. 47 (2001) 617-623
26. Verheul H.M., and Pinedo H.M. The importance of platelet counts and their contents in cancer. Clin. Cancer Res. 9 (2003) 3219-3221
27. Pepe M.S., Janes H., Longton G., Leisenring W., and Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am. J. Epidemiol. 159 9 (2004) 882-890 (May 1)
28. Silha J.V., Krsek M., Sucharda P., and Murphy L.J. Angiogenic factors are elevated in overweight and obese individuals. Int. J. Obes. 29 (2005) 1308-1314
29. Argiles J.M., Busquets S., and Lopez-Soriano F. The pivotal role of cytokines in muscle wasting during cancer. Int. J. Biochem. Cell Biol. 37 (2005) 1609-1619
30. Kotler D.P. Cachexia. Ann. Intern. Med. 133 (2000) 622-634
31. Shimada H., Nabeya Y., and Tagawa M. Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci. 94 (2003) 628-632
32. Ren Y., Cao B., Law S., et al. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin. Cancer Res. 11 (2005) 6190-6197
33. Krzystek-Korpacka M., Matusiewicz M., Diakowska D., Grabowski K., Blachut K., and Banas T. Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Cancer Lett. 249 (2007) 171-177
34. Krzystek-Korpacka M., Matusiewicz M., Diakowska D., et al. Serum midkine depends on lymph node involvement and correlates with circulating VEGF-C in esophageal squamous cell carcinoma. Biomarkers 12 (2007) 403-413
35. Ding S., Lin S., Dong X., et al. Potential prognostic value of circulating levels of vascular endothelial growth factor-A in patients with gastric cancer. In Vivo 19 (2005) 793-795
36. Obata Y., Kikuchi S., Lin Y., et al. Serum midkine concentrations and gastric cancer. Cancer Sci. 96 (2005) 54-56
37. Macri A., Versaci A., and Loddo S. Serum levels of interleukin 1beta, interleukin 8 and tumour necrosis factor alpha as markers of gastric cancer. Biomarkers 11 (2006) 184-193
38. Saharinen P., Tammela T., Karkkainen M.J., and Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 25 (2004) 387-395
39. Ristimaki A., Narko K., Enholm B., Joukov V., and Alitalo K. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J. Biol. Chem. 273 (1998) 8413-8418
40. Wigmore S.J., Fearon K.C., Maingay J.P., Lai P.B., and Ross J.A. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am. J. Physiol. 273 (1997) E720-E726
41. Tisdale M.J. Pathogenesis of cancer cachexia. J. Support Oncol. 1 (2003) 159-168
42. Ebrahimi B., Tucker S.L., Li D., Abbruzzese J.L., and Kurzrock R. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer 101 (2004) 2727-2736
43. Dimitriu C., Martignoni M.E., Bachmann J., et al. Clinical impact of cachexia on survival and outcome of cancer patients. Rom. J. Internal Med. 43 (2005) 173-185
44. Villiger P.M., Geng Y., and Lotz M. Induction of cytokine expression by leukemia inhibitory factor. J. Clin. Invest. 91 (1993) 1575-1581
45. Watchorn T.M., Dowidar N., Dejong C.H., Waddell I.D., Garden O.J., and Ross J.A. The cachectic mediator proteolysis inducing factor activates NF-kappaB and STAT3 in human Kupffer cells and monocytes. Int. J. Oncol. 27 (2005) 1105-1111
46. Pfitzenmaier J., Vessella R., Higano C.S., Noteboom J.L., Wallace Jr. D., and Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer 97 (2003) 1211-1216
47. Ratovitski E.A., Kotzbauer P.T., Milbrandt J., Lowenstein Ch.J., and Burrow Ch.R. Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases. J. Biol. Chem. 273 (1998) 3654-3660
48. Rebbaa A., Chou P.M., and Mirkin B.L. Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Mol. Med. 7 (2001) 393-400
49. Watchorn T.M., Waddell I., Dowidar N., and Ross J.A. Proteolysis-inducing factor regulates hepatic gene expression via the transcription factors NF-(kappa)B and STAT3. FASEB J. 15 (2001) 562-564
50. Sato W., Kadomatsu K., Yuzawa Y., et al. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J. Immunol. 167 (2001) 3463-3469
51. Sumi Y., Muramatsu H., Takei Y., Hata K., Ueda M., and Muramatsu T. Midkine, a heparin-binding growth factor promotes growth and glycosaminoglycan synthesis of endothelial cells through its action on smooth muscle cells in an artificial blood vessel model. J. Cell Sci. 115 (2002) 2659-2667
52. Morimura M., Ishiko O., Sumi T., Yoshida H., and Ogita S. Angiogenesis in adipose tissues and skeletal muscles with rebound weight-gain after diet-restriction in rabbits. Int. J. Mol. Med. 8 (2001) 499-503
53. Werynska B., Kosacka M., Golecki M., and Jankowska R. VEGF in the cancer anorexia-cachexia syndrome in patients with lung cancer. Pneumonol. Alergol. Pol. 74 (2006) 186-190
54. Boedefeld W.M., Bland K.I., and Heslin M.J. Recent insights into angiogenesis, apoptosis, invasion and metastasis in colorectal carcinoma. Ann. Surg. Oncol. 10 (2003) 839-851
55. Macias I., Garcia-Perez S., Ruiz-Tudela M., Medina F., Chozas N., and Giron-Gonzales J.A. Modification of pro- and anti-inflammatory cytokines and vascular-related molecules by tumor necrosis factor-α blockade in patients with rheumatoid arthritis. J. Rheumatol. 32 (2005) 2102-2108
56. Kuzuya M., Kanda S., Koike T., Suzuki Y., and Iguchi A. Lack of correlation between total lymphocyte count and nutritional status in the elderly. Clin. Nutr. 24 (2005) 427-432
57. Seres D.S. Surrogate nutrition markers, malnutrition, and adequacy of nutrition support. Nutr. Clin. Prac. 20 (2005) 308-313
58. Ockenga I., and Valentini L. Review article: anorexia and cachexia in gastrointestinal cancer. Aliment. Pharmacol. Ther. 22 (2005) 583-594